Protagonist Therapeutics (PTGX) Stock Price, News & Analysis

Company Overview

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Key Stats

• Today's Range: $43.62 to $44.84
• 50-Day Range: $35.09 to $59.76
• 52-Week Range: $24.22 to $60.60
• Volume: 634,255 shs
• Average Volume: 855,688 shs
• Market Capitalization: $2.73 billion
• P/E Ratio: 16.73
• Dividend Yield: N/A
• Price Target: $65.44
• Consensus Rating: Buy

Protagonist Therapeutics Stock Analysis - MarketRank™

Protagonist Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 303rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Protagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Protagonist Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Protagonist Therapeutics are expected to decrease in the coming year, from $2.43 to ($0.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Protagonist Therapeutics is 16.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.67.

Price to Earnings Ratio vs. Sector

The P/E ratio of Protagonist Therapeutics is 16.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.14.

Price to Book Value per Share Ratio

Protagonist Therapeutics has a P/B Ratio of 7.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.35% of the float of Protagonist Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Protagonist Therapeutics has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Protagonist Therapeutics has recently decreased by 8.19%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Protagonist Therapeutics does not currently pay a dividend.

Dividend Growth

Protagonist Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.35% of the float of Protagonist Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Protagonist Therapeutics has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Protagonist Therapeutics has recently decreased by 8.19%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.15

News Sentiment

Protagonist Therapeutics has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Protagonist Therapeutics this week, compared to 5 articles on an average week.

MarketBeat Follows

Only 1 people have added Protagonist Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,665,786.00 in company stock.

Percentage Held by Insiders

Only 5.40% of the stock of Protagonist Therapeutics is held by insiders.

Percentage Held by Institutions

98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PTGX Stock Analysis - Frequently Asked Questions

How have PTGX shares performed this year?

Protagonist Therapeutics' stock was trading at $38.60 at the start of the year. Since then, PTGX shares have increased by 15.3% and is now trading at $44.49.
View the best growth stocks for 2025 here.

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) posted its quarterly earnings data on Friday, February, 21st. The company reported $1.98 EPS for the quarter, topping the consensus estimate of ($0.09) by $2.07. The business earned $170.64 million during the quarter, compared to the consensus estimate of $56.65 million. Protagonist Therapeutics had a net margin of 52.76% and a trailing twelve-month return on equity of 34.68%.

When did Protagonist Therapeutics IPO?

Protagonist Therapeutics (PTGX) raised $70 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' top institutional investors include GAMMA Investing LLC (0.09%), New York State Teachers Retirement System (0.08%), Assenagon Asset Management S.A. (0.07%) and State of Alaska Department of Revenue (0.05%). Insiders that own company stock include Dinesh V Ph D Patel, Suneel Gupta, Arturo Md Molina, Asif Ali and William D Waddill.
View institutional ownership trends.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Protagonist Therapeutics investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and AUO (AUOTY).

Company Calendar

• Last Earnings: 2/21/2025
• Today: 4/26/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PTGX
• CIK: 1377121
• Web: www.protagonist-inc.com
• Phone: (510) 474-0170
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $65.44
• High Stock Price Target: $80.00
• Low Stock Price Target: $38.00
• Potential Upside/Downside: +47.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $4.20
• Trailing P/E Ratio: 16.73
• Forward P/E Ratio: 18.31
• P/E Growth: N/A
• Net Income: $-78,960,000.00
• Net Margins: 52.76%
• Pretax Margin: 53.45%
• Return on Equity: 34.68%
• Return on Assets: 30.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.69
• Quick Ratio: 10.70

Sales & Book Value

• Annual Sales: $434.43 million
• Price / Sales: 6.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.84 per share
• Price / Book: 7.62

Miscellaneous

• Outstanding Shares: 61,384,000
• Free Float: 56,380,000
• Market Cap: $2.73 billion
• Optionable: Optionable
• Beta: 2.30